Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2022/09/045596
CTRI/2022/09/045596
Not Yet Recruiting
N/A

Efficacy and Safety of Dapagliflozin in progression of Chronic Kidney Disease in patients with type 2 Diabetes Mellitus: A Randomised Controlled Study

Maulana Azad Medical College Delhi0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Maulana Azad Medical College Delhi
Status
Not Yet Recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Maulana Azad Medical College Delhi

Eligibility Criteria

Inclusion Criteria

  • •1\. Patients with diagnosis of CKD with type 2 Diabetes Mellitus with HbA1c \<8% who had\-
  • •eGFR of 30\-60ml/min/1\.73m2
  • •Urinary Albumin to Creatinine ratio 200\-5000mg/g
  • •2\. Patients who are on ACE inhibitors or ARBs for at least 4 weeks before screening.

Exclusion Criteria

  • •1\. Patients with Type 1 diabetes, lupus nephritis, Rheumatoid arthritis, Cancer and
  • •Neurodegenerative disorders
  • •2\. Patients have received immunosuppressive therapy within 6 months.
  • •3\. Pregnant patients and nursing mothers.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not Yet Recruiting
N/A
Dapagliflozin in Heart Failure
CTRI/2022/11/047725Sanjay Kumar R
Not Yet Recruiting
N/A
Dapagliflozin is a licensed medicine used for reducing blood sugar in people with diabetes and this study will test whether it can also reduce the stiffness in the liver which commonly occurs in diabetes.Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications
CTRI/2019/05/019286Dr Shashi Panicker
Recruiting
N/A
Examination of the efficacy of dapagliflozin in patients with type 2 diabetesType 2 diabetes
JPRN-UMIN000021954Tonami general hospital Department of diabetes mellitus and endocrinology200
Recruiting
Phase 3
The efficacy of dapagliflozin in preventing contrast-associated acute kidney injuryAcute Coronary Syndrome.ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
IRCT20181026041471N1Rajaie Cardiovascular Medical and Research Institute1,500
Not Yet Recruiting
Phase 2
Effectiveness and safety of oral dapagliflozin in reducing urinary leakage of protein in children with reduced kidney function.
CTRI/2022/04/042032All India Institute of Medical Sciences